Op2Lysis is excited to announce the receipt of public funding from the Normandy Region and the 🇪🇺 FEDER FSE+ FTJ Normandie program for its THROMBO-STROKE collaborative project. Running from October 2024 to September 2027, the project aims to develop innovative models for ischemic stroke ⚡🧠 by addressing the critical challenge of clot heterogeneity. In collaboration […]
24 July 2024 💥We are delighted to announce that the O2L-001 technology developed by Op2Lysis to treat massive and deep cerebral haemorrhage 🩸🧠 has reached a new milestone. The first “Dose Range Finding” safety study has produced very positive results. This success means that highly effective doses can be used in clinical trials.
There are still a few days left to wish a very Happy New Year 2024 to our community, our investors, our readers and all those who make the Op2Lysis program live, progress and bring new hope to hemorrhagic stroke patients every day 🧓🧠🩸. We are therefore delighted to share with you the progress made in […]
Op2Lysis has been nominated for the Prix GALIEN USA 2023, in the Best StartUp category. The Prix Galien recognises outstanding achievements in improving human health and well-being around the world through the development of drugs, medical devices and other innovative approaches to better manage disease. The press release is available below:
The World Intracranial Hemorrhage Conference (WICH) meets every two years and brings together neurologists, neurosurgeons, researchers and clinicians from all fields, healthcare providers, students and community members from around the world to provide a unique opportunity to exchange ideas and share research and clinical innovations in the field of intracranial haemorrhage. The WICH 2023 conference […]
Op2Lysis was awarded a Deeptech Development Grant (ADD) to manufacture the clinical batch of OptPA, the active substance in O2L-001, for phase 1/2 in patients suffering from cerebral haemorrhage. The press release:
The European Innovation Council and SME Executive Agency (EISMA) has validated the EIC Accelerator grant contract and followed the initial recommandation of the independent jury by awarding us the maximum support, i.e. a grant of €2.5M to industrialise O2L-001. The press release: